These results suggests that in the future research on FOXM1 inhibitors, we also need to consider the ratio of M1 and M2 macrophages in vivo to maintain the balance of TAMs in the tumor microenvironment, which may help develop an attractive drug for controlling drug-resistant and difficult-to-suppress breast cancers. The gene discussed is FOXM1; the disease is breast carcinoma.